Clinical Trials Logo

Breakthrough Bleeding clinical trials

View clinical trials related to Breakthrough Bleeding.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02903121 Completed - Bleeding Clinical Trials

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

Tamoxifen/BTB
Start date: January 20, 2017
Phase: Phase 4
Study type: Interventional

The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women. The only study to demonstrate a sustained reduction in bleeding lasting for two months was the selective estrogen receptor modulator (SERM) tamoxifen in users of the levonogestrel (LNG) contraceptive implant. Based on the investigators encouraging preliminary data of tamoxifen and ENG implant users, the investigators plan to perform additional studies on the impact of tamoxifen on the breakthrough bleeding experience by ENG implant users.

NCT ID: NCT01469585 Completed - Clinical trials for Breakthrough Bleeding

Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases

Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effects (good and bad) of subantimicrobial dose doxycycline on the irregular bleeding women experience when taking continuous oral contraceptive pills. This research is being done because currently, there is no effective treatment for this condition. Findings from this study could help to decrease the side effects of birth control pills and decrease unplanned pregnancies.

NCT ID: NCT00475553 Completed - Clinical trials for Breakthrough Bleeding

Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®

Start date: May 2006
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate the best way to manage breakthrough spotting and bleeding during an extended use regimen of NuvaRing®. Ease of use and acceptability of a flexible regimen of NuvaRing® will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and headaches will be made between a standard 21/7 regimen and an extended regimen.

NCT ID: NCT00394771 Completed - Clinical trials for Breakthrough Bleeding

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Start date: October 2006
Phase: Phase 2
Study type: Interventional

This is a 4-arm study to evaluate and compare bleeding patterns between three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary

NCT ID: NCT00120913 Completed - Clinical trials for Breakthrough Bleeding

Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?

Start date: n/a
Phase: N/A
Study type: Interventional

While there may be a decrease in the total number of bleeding days women experience with continuous-dosed COCs (no menstrual withdrawal week), these regimens frequently result in an increased number of “breakthrough” or non-scheduled bleeding days. Breakthrough bleeding is among the main reasons cited for discontinuation of combined COCs dosed traditionally (3 weeks of active pill, 1 week of placebo) or continuously, and may offset the perceived benefit of fewer withdrawal bleeding events for many women taking continuous-dosed COCs. The exact mechanisms responsible for breakthrough bleeding patterns during hormonal contraception are unknown and may be related to the pill formulation. This study is to determine whether progestin type or estrogen dose influences bleeding patterns, side effects, or satisfaction with combined oral contraceptives (COC) dosed continuously.